Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppresses PD-L1 expression and amplifies tumor-infiltrating T-cell response, thus exerting anticancer effects. This compound is particularly utilized in the investigation of colorectal cancer [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | PD-L1-IN-2, a Naamidine J derivative, serves as a promising antineoplastic immunomodulator by hindering PD-L1 activity. In vivo studies indicate that it suppresses PD-L1 expression and amplifies tumor-infiltrating T-cell response, thus exerting anticancer effects. This compound is particularly utilized in the investigation of colorectal cancer [1]. |
In vitro | PD-L1-IN-2 (compound 11c) exhibits an IC50 value of 31.7μM against RKO cells [1]. PD-L1-IN-2, within a concentration range of 0-10 μM and over a time course of 0-24 hours, inhibits PD-L1 expression in RKO cells in both a dose-dependent and time-dependent manner [1]. Additionally, PD-L1-IN-2 promotes the turnover of the PD-L1 protein, as cells treated with PD-L1-IN-2 show an accelerated PD-L1 turnover rate compared to untreated cells in a CHX pulse-chase assay [1]. |
In vivo | PD-L1-IN-2 (compound 11c) administered intraperitoneally at 25/50 mg/kg once daily for 16 days resulted in tumor size reduction, with the 50 mg/kg group exhibiting a 45% inhibition rate and a significantly lower average tumor weight compared to the PBS group [1]. |
Molecular Weight | 586.68 |
Formula | C33H38N4O6 |
CAS No. | 2894733-91-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
PD-L1-IN-2 2894733-91-4 Apoptosis Cell Cycle/Checkpoint Immunology/Inflammation PD-1/PD-L1 inhibitor inhibit